Prevalence and detection of low-allele-fraction variants in clinical cancer samples

DSpace/Manakin Repository

Prevalence and detection of low-allele-fraction variants in clinical cancer samples

Citable link to this page

 

 
Title: Prevalence and detection of low-allele-fraction variants in clinical cancer samples
Author: Shin, Hyun-Tae; Choi, Yoon-La; Yun, Jae Won; Kim, Nayoung K. D.; Kim, Sook-Young; Jeon, Hyo Jeong; Nam, Jae-Yong; Lee, Chung; Ryu, Daeun; Kim, Sang Cheol; Park, Kyunghee; Lee, Eunjin; Bae, Joon Seol; Son, Dae Soon; Joung, Je-Gun; Lee, Jeeyun; Kim, Seung Tae; Ahn, Myung-Ju; Lee, Se-Hoon; Ahn, Jin Seok; Lee, Woo Yong; Oh, Bo Young; Park, Yeon Hee; Lee, Jeong Eon; Lee, Kwang Hyuk; Kim, Hee Cheol; Kim, Kyoung-Mee; Im, Young-Hyuck; Park, Keunchil; Park, Peter J.; Park, Woong-Yang

Note: Order does not necessarily reflect citation order of authors.

Citation: Shin, H., Y. Choi, J. W. Yun, N. K. D. Kim, S. Kim, H. J. Jeon, J. Nam, et al. 2017. “Prevalence and detection of low-allele-fraction variants in clinical cancer samples.” Nature Communications 8 (1): 1377. doi:10.1038/s41467-017-01470-y. http://dx.doi.org/10.1038/s41467-017-01470-y.
Full Text & Related Files:
Abstract: Accurate detection of genomic alterations using high-throughput sequencing is an essential component of precision cancer medicine. We characterize the variant allele fractions (VAFs) of somatic single nucleotide variants and indels across 5095 clinical samples profiled using a custom panel, CancerSCAN. Our results demonstrate that a significant fraction of clinically actionable variants have low VAFs, often due to low tumor purity and treatment-induced mutations. The percentages of mutations under 5% VAF across hotspots in EGFR, KRAS, PIK3CA, and BRAF are 16%, 11%, 12%, and 10%, respectively, with 24% for EGFR T790M and 17% for PIK3CA E545. For clinical relevance, we describe two patients for whom targeted therapy achieved remission despite low VAF mutations. We also characterize the read depths necessary to achieve sensitivity and specificity comparable to current laboratory assays. These results show that capturing low VAF mutations at hotspots by sufficient sequencing coverage and carefully tuned algorithms is imperative for a clinical assay.
Published Version: doi:10.1038/s41467-017-01470-y
Other Sources: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5680209/pdf/
Terms of Use: This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA
Citable link to this page: http://nrs.harvard.edu/urn-3:HUL.InstRepos:34493057
Downloads of this work:

Show full Dublin Core record

This item appears in the following Collection(s)

 
 

Search DASH


Advanced Search
 
 

Submitters